Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 9%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is a promising stock with strong potential for growth due to its leading position in the life sciences tools and diagnostics market, as well as its strategic initiatives aimed at improving its business mix and efficiency. The upcoming acquisition of Wilson Wolf, a high-growth cell therapy tools company, is also expected to be a major catalyst for the company's growth. While the company's near-term outlook may be muted due to market conditions and regulatory risks, we believe its long-term growth prospects remain strong. With its strong financials and commitment to sustainability, Bio-Techne is well positioned to capitalize on the rebound of biotech funding and maintain its competitive edge in the market.

Bears say

Bio-Techne is facing several key risks that could negatively impact its stock, including potential delays in end market recovery, concerns about loss of market share to larger competitors in the research reagents space, potential disappointment in cell therapy progress which accounts for ~15% of the company's sales, and any potential issues with acquisitions or integration. The company has implemented sustainability measures, but there is no direct link between these metrics and executive compensation. There may also be concerns about potential disruption from AI and software technologies in the life science industry, but the company's track record in M&A gives some confidence in its ability to adapt to changing market conditions. Despite some positive developments in the recent quarter such as strong bookings for its COMET instrument and growth in its diagnostics business, there are still headwinds such as the cell therapy air pocket and the impact of an OEM order pull-forward, predicting flat organic growth for the next quarter. Overall, the outlook for Bio-Techne's stock is negative due to a combination of risks and uncertainties in the life sciences industry and the company's specific segment exposure.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 9% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Jul 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $68.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $68.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.